1. Chang HL, Tang CH, Hsu YM,Wan L, Chang YF, Lin CT, et al. Nosocomial outbreak of infection with multidrug-resistant Acinetobacter baumannii in a medical center in Taiwan. Infect Control Hosp Epidemiol. 2009; 30(1): 34–8.
2. Kokkonouzis I, Christou I, Athanasopoulos I, Saridis N, Skoufaras V. Multiple lung abscesses due to acinetobacter infection: a case report. Cases J. 2009; 2:9347.
3. Rana MA, Rahman BA, Mady A, Odat MA, Alharth A, Ramadan Oel S, et al. Intra-pleural colistin than esulfonate therapy for pleural infection caused by carbapenem-resistant Acinetobacter baumannii: a successful case report. Infect Dis Rep. 2014; 6(3): 5413.
4. Manchanda V, Sanchaita S, Singh NP. Multidrug Resistant Acinetobacter. J Glob Infect Dis. 2010; 2(3): 291-304.
5. Sullivan DR, Shields J, Netzer G. Fatal case of multidrug resistant Acinetobacter baumannii necrotizing fasciitis. The American Surgeon. 2010; 76(6): 651–3.
6. Feizabadi M M, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among Acinetobacter spp. Isolated from patients at Tehran hospitals. Jpn J Infect Dis. 2008; 61(4): 274-8.
7. Wayne, PA, USA: Clinical and Laboratory Standards Institute (CLSI). M100-S21: Performance standards for antimicrobial susceptibility testing. 2012; 32. 21st Informational Supplement.
8. Tsakiridou E, Makris D, Daniil Z, Manoulakas E, Chatzipantazi V, Viachos O, et al. Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. Biomed Res Int. 2014: Article ID 193516.
9. Nhu NTK, Lan NP, Campbell JI, Parry CM, Thompson C, Tuyen HT, et al. Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator- associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. J Med Microbiol. 2014; 63: 1386–94.
10. Ayraud-Thevenot S, Huart C, Mimoz O. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect. 2012; 82(4): 290–2.
11. Davis JS, McMillan M, Swaminathan A, Kelly JA, Piera KE, Baird RW, et al. A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols. Chest. 2014; 146(4): 1038-45.
12. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 2009; 8:18.
13. Chaari A, Mnif B, Bahloul M, MahjoubiF, Chtara K, Turki O, Gharbi N,Chelly H, Hammami A, Bouaziz M. Acinetobacterbaumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013; 17(12): e1225–8.
14. Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-ac- quired pneumonia caused by Acinetobacter baumannii. J Infect. 2010; 61(3): 212–8.
15. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006; 57(6): 1251–4